Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07495332 · ClinicalTrials.gov registry record · NA
Siemens Biomarker Multi-modality
A NA study, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT07495332: Recruiting NA study, sponsored by Duke University.
NCT07495332 is a NA study that is actively recruiting participants, run by Duke University. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07495332, a NA study, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.
Primary Outcome
The percentage of patients with hepatic steatosis by MRI-PDFF who have positive CT-PDFF.
Interventions
- DIAGNOSTIC_TEST Magnetic Resonance Imaging (MRI)
- DIAGNOSTIC_TEST Ultrasound
- DIAGNOSTIC_TEST Photon-counting CT (PCCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2027-05 |
| Phase | NA |
What NCT07495332 shows while recruiting
NCT07495332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT07495332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07495332 about?
NCT07495332 is a clinical study titled "Siemens Biomarker Multi-modality". The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just ...
What is the current status of trial NCT07495332?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2026-03-27. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07495332?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Ultrasound (DIAGNOSTIC_TEST), Photon-counting CT (PCCT) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07495332?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07495332's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI